Can omeprazole reduce the risk of Barrett’s esophagus progression to adenocarcinoma and what evidence supports its role in cancer prevention in these patients?
Lakshya KumarExplorer
Can omeprazole reduce the risk of Barrett’s esophagus progression to adenocarcinoma?
Share
1. Omeprazole may lower the risk of Barrett’s esophagus progressing to adenocarcinoma by reducing acid reflux, thereby decreasing esophageal irritation and potential cell changes.
2. Studies suggest omeprazole can help prevent adenocarcinoma in patients with Barrett’s esophagus by controlling acid exposure, which potentially reduces inflammation and cellular damage.
3. Evidence indicates that omeprazole, by managing gastroesophageal reflux, could indirectly slow or prevent the progression from Barrett’s esophagus to esophageal adenocarcinoma.